Table 2:

MR findings in the amygdala/hippocampus and the time interval from the onset of neurological symptoms

Time of Imaging with Reference to Symptom Onset		Imaging Findings in the Amygdala/Hippocampus
	Plain CT	T1WI	T2WI	FLAIR	DWI	ADC Value	Gd-T1WI	Others on MR
	Abnormal findings	Low	High	High	High	Reduction	Abnormal enhancement	Atophic change
Early period, days 1–2 (n = 4 patients)	0/3 (0%)	2/4 (50%)	2/4 (50%)	2/3 (67%)	2/2 (100%)	2/2 (100%)	0/2 (0%)	0/4 (0%)
Middle period, days 3–30 (n = 4 patients)		5/6 (83%)	4/6 (67%)	5/6 (83%)	3/5 (60%)	1/3 (33%)	0/2 (0%)	2/6 (33%)
Late period, days 31+ (n = 4 patients)		0/4 (0%)	0/4 (0%)	0/4 (0%)	0/4 (0%)	0/2 (0%)	0/2 (0%)	4/4 (100%)

Note:—Gd-T1WI indicates gadolinium-diethylene triaminepentaacetic acid T1-weighted imaging; ADC, apparent diffusion coefficient; T1WI, T1-weighted imaging; T2WI, T2-weighted imaging; FLAIR, fluid-attenuated inversion recovery; DWI, diffusion-weighted imaging.